



Gurpreet Rekhi

Senior Research Officer, North Region, Institute of Mental Health, Singapore

Research Interests:

- Negative Symptoms in Schizophrenia
- Bipolar Disorders
- Prodromal Psychosis

Email: gurpreet_rekhi@imh.com.sg

Research Profile:

Research Gate: [Gurpreet Rekhi](#)

<https://orcid.org/0000-0002-9014-5718>

Biography

Dr. Gurpreet Rekhi is a Senior Research Officer at the Institute of Mental Health (IMH). She obtained her basic medical degree and specialty training in psychiatry from the M.S. University, India in 2005. She pursued Senior Residency in psychiatry at Dr RML Hospital, New Delhi, India and following that, worked as a Medical Officer (Psychiatry) at Alexandra hospital, Singapore.

In 2009, she joined IMH as a Researcher at IMH and since then, she has led studies investigating various aspects of psychosis and has authored many manuscripts on the topic, particularly around negative syndromes. She was co-investigator for various schizophrenia related Clinical trials conducted at IMH. Currently, she is the site phenotyping leader for the Asian Bipolar Genetics Network (A-BIG-NET) study at IMH and investigator for the Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT) study. In parallel, Dr Rekhi trains and supervises the research team on psychiatric research assessments on psychopathology. She is involved in the supervision and teaching of interns attached with her studies.

Dr. Rekhi's research interests are in prodromal and negative symptoms in schizophrenia, and bipolar disorders.

Selected Publications

- Wolpe, N., Perrottelli, A., Giuliani, L., Yang, Z., **Rekhi, G.**, Jones, P. B., ... Fernandez-Egea, E. (2025). Measuring the clinical dimensions of negative symptoms through the Positive and Negative Syndrome Scale. *European Neuropsychopharmacology*, 93, 68–76.
<https://doi.org/10.1016/j.euroneuro.2024.12.016>
- **Rekhi, Gurpreet**, Saw, Y. E., Lim, K., Keefe, R. S. E., & Lee, J. (2023). Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia. *Brain Sciences*, 13(2).
<https://doi.org/10.3390/brainsci13020215>
- Li, Y., **Rekhi, G.**, Ang, M. S., & Lee, J. (2023). Impact of negative symptoms on health-related quality of life in schizophrenia. *Frontiers in Psychiatry*, 14. Retrieved from
<https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1252354>
- **Rekhi, Gurpreet**, Ang, M. S., Chan, Y. H., Fernandez-Egea, E., Kirkpatrick, B., & Lee, J. (2022). Defining negative symptoms remission in schizophrenia using the Brief Negative Symptom Scale. *Revista de Psiquiatría y Salud Mental (English Edition)*, 15(1), 3–13.
<https://doi.org/10.1016/j.rpsmen.2022.01.007>
- **Rekhi, G.**, Alphs, L., Ang, M. S., & Lee, J. (2019). Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia. *Eur Neuropsychopharmacol*, 29(12), 1433–1441.
<https://doi.org/10.1016/j.euroneuro.2019.10.009>
- **Rekhi, Gurpreet**, Ang, M. S., Yuen, C. K. Y., Ng, W. Y., & Lee, J. (2019). Assessing negative symptoms in schizophrenia: Validity of the clinical assessment interview for negative symptoms in Singapore. *Schizophrenia Research*, 206, 177–182.
<https://doi.org/10.1016/j.schres.2018.11.029>
- Ang, M. S., **Rekhi, G.**, & Lee, J. (2019). Validation of the Brief Negative Symptom Scale and its association with functioning. *Schizophr Res*, 208, 97–104.
<https://doi.org/10.1016/j.schres.2019.04.005>
- **Rekhi, G.**, Ng, W. Y., & Lee, J. (2018). Clinical utility of the Calgary Depression Scale for Schizophrenia in individuals at ultra-high risk of psychosis. *Schizophr Res*, 193, 423–427.
<https://doi.org/10.1016/j.schres.2017.06.056>
- **Rekhi, Gurpreet**, Khyne, T. T., & Lee, J. (2016). Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia. *General Hospital Psychiatry*, 43, 46–50.
<https://doi.org/10.1016/j.genhosppsy.2016.09.005>

- Lim, J., **Rekhi, G.**, Rapisarda, A., Lam, M., Kraus, M., Keefe, R. S., & Lee, J. (2015). Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis—Findings from the Longitudinal Youth at Risk Study (LYRIKS). *Schizophr Res*, 164(1–3), 8–14.
<https://doi.org/10.1016/j.schres.2015.03.007>
- Vaingankar, J. A., **Rekhi, G.**, Subramaniam, M., Abidin, E., & Chong, S. A. (2013). Age of onset of life-time mental disorders and treatment contact. *Social Psychiatry and Psychiatric Epidemiology*, 48(5), 835–843.
<https://doi.org/10.1007/s00127-012-0601-y>